Home / Central Data Catalog / FRESH-PEF73983-EN
central

COVID-19 vaccine cohort for special populations

France, 2021 - 2024
Reference ID
FRESH-PEF73983-en
Producer(s)
Linda;WITTKOP, Paul;LOUBET, Odile;LAUNAY
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
43
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Quality standards
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF73983-en
    Title

    COVID-19 vaccine cohort for special populations
    Abbreviation or Acronym

    ANRS 0001 S COV-POPART
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data','Biological data','Socio-demographic data','Participant-reported health data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Clinical immunology health theme
    Infectious disease medicine health theme
    COVID-19 cim-11
    Keywords
    Covid-19 vaccines / Immunogenicity / Immunosuppression / At-risk populations

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Child, Preschool (2 to 5 years)","concept":{"vocab":"MeSH","vocabURI":"D002675"}},{"value":"Child (6 to 12 years)","concept":{"vocab":"MeSH","vocabURI":"D002648"}},{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}},{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"General population","level_type_clusion_other":"","clusion_I":"","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Linda;WITTKOP
    Paul;LOUBET
    Odile;LAUNAY
    Producers
    Name Role
    AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) sponsor
    Funding Agency/Sponsor
    Name
    AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE)

    Study authorization

    Agency
    Agency name
    ANSM

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2021-01-01 2024-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"Transcription","vocab":"CESSDA"},"value":"Converting or copying information into a structured record"}

    Quality standards

    Quality standards
    Standard
    ['Concomitant Pathologies: ICD-10. Ongoing Treatments: WHO Drug']
    Other quality statement

    ['CMG-EC quality system (ISO 9001 certified), consistency checks after data entry, data monitoring according to a monitoring plan: remotely + on site by a specialised CRO (return to source file for data management and verification)']

    Data Access

    Access conditions

    Via the PRS form, which must be validated by the cohort's Steering Committee and Scientific Board.
    Availability Status

    {"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}

    Contacts

    Contacts
    Name Email
    Sophie;GUILMIN-CREPON sophie.guilmin-crepon@aphp.fr
    Aude;BARQUIN aude.barquin@inserm.fr
    Back to Catalog